Evolent account plan
specialty-focused value-based care
At a glance
Evolent manages oncology, cardiology and musculoskeletal care for US health plans: $1,876.2 million FY2025 revenue, about 4,200 employees.
Evolent (NYSE: EVH), headquartered in Arlington, Virginia, manages specialty care for people with complex conditions, chiefly cancer, cardiovascular disease and musculoskeletal diagnoses, on behalf of health plans and other risk-bearing payers; all revenue is recognized in the United States. It works through specialist networks, evidence-based clinical pathways and its own technology (the CarePro workflow platform and the Identifi platform). FY2025 revenue fell 26.6% to $1,876.2 million, and the net loss attributable to common shareholders was $579.4 million, driven by a $398.0 million non-cash goodwill impairment. It had about 4,200 employees as of February 16, 2026, with offices in the US, Pune (India) and Manila (Philippines). Founded in 2011, it listed on the NYSE in June 2015.
Business units
Performance Suite
$1,127.3 million FY2025 revenue (about 60%, computed)Specialty care management under capitation: Evolent takes on the cost of in-scope medical claims for a fixed fee per member per month. Revenue fell in 2025 after one customer moved to the Specialty Technology and Services Suite and others narrowed scope, then rebounded to $564.3 million in Q3 2026 (Q3 2025: $286.9 million) with the Aetna and Highmark launches, on 7,195 thousand average lives at $26.14 PMPM.
Specialty Technology and Services Suite
$353.2 million FY2025 revenue (about 19%, computed)The same oncology, cardiology, musculoskeletal, advanced imaging and diagnostics management under non-capitation (ASO) arrangements, including the heritage of National Imaging Associates (NIA). It covered 77,983 thousand average lives in 2025 at $0.38 PMPM; Q3 2026 revenue fell to $72.8 million (Q3 2025: $93.3 million).
Administrative Services
$226.7 million FY2025 revenue (about 12%, computed)Recurring multi-year platform and operations contracts on the Identifi platform: health plan services, third-party administration, pharmacy benefit management, risk management and analytics. Q3 2026 revenue was $48.3 million (Q3 2025: $57.8 million), and management expects some planned client attrition in 2027.
Cases
$169.0 million FY2025 revenue (about 9%, computed)Services billed per case: surgery management for musculoskeletal conditions (Implantable Provider Group, IPG) and advance care planning (Vital Decisions). It handled 53 thousand cases in 2025 at $3,168 per case; the largest Surgical Management customer renewed for four more years in Q3 2026.
Strategic priorities
- Oncology as the core business
- CEO Seth Blackley expects oncology to represent over 70% of Evolent's 2027 revenue. Evolent is embedding clinical pathways directly into the EMRs of leading oncology groups and expanding Member Navigation.
- AI-driven prior-authorization review
- AuthIntelligence, built from the 2024 Machinify acquisition, evaluates about half of the prior-authorization volume that needed manual review, about 1 million cases a year. The target is more than 80% of manual auths, about 2 million cases, by end 2027; company policy forbids using AI to deny care.
- Renewals and expansions with existing payers
- Seven new revenue agreements and renewals were signed year to date by Q3 2026, including a national payer adding 11 states to an existing 39 in oncology and an existing client expanding oncology to about 1 million Commercial lives from January 1, 2027.
- Margin and cash over revenue growth
- CFO Mario Ramos says Evolent is prioritizing margin and cash generation over revenue growth, with a 2027 Adjusted EBITDA midpoint expected at $150 million or higher, helped by Performance Suite margin maturation and an enterprise-wide cost review.
- Fixing the capital structure
- Evolent plans to deploy up to $50 million to reduce debt by year end 2026 and is evaluating capital markets and strategic alternatives to improve leverage and its 2029 maturities within 12 to 24 months.
Latest results
In Q3 2026 (three months to September 30, 2026) revenue rose 51.3% year on year to $725.4 million, mainly from $280.1 million of new Performance Suite go-lives and expanded oncology services for an existing customer. Net loss attributable to common shareholders narrowed to $23.6 million from $26.9 million, while Adjusted EBITDA fell to $34.3 million (4.7% margin, down from 8.1%) as low-margin capitated revenue grew. The Medical Expense Ratio was 93.0% (Q3 2025: 85.0%), and SG&A fell 5.8% to $73.1 million. Nine-month revenue was $1,874.1 million, up 33.2%. Full-year 2026 guidance is revenue of $2.6 billion to $2.7 billion (reiterated) and Adjusted EBITDA of $130.0 million to $135.0 million (raised), with capital expenditure of $26 million to $28 million.
Investments and deals
- Sale of Evolent Care Partners
- The ACO / total cost of care business was sold for $100.0 million plus up to $13.0 million contingent, closing December 5, 2025; cash proceeds were $91.3 million and $82.8 million of term loan was repaid.
- 2025 refinancing
- $166.8 million of 2031 convertible notes were issued in August 2025, the 2025 notes retired, $40.0 million of shares repurchased, and the Series A Preferred Stock exchanged for a $175.0 million second-lien term loan with Ares.
- Machinify and AuthIntelligence
- The 2024 Machinify acquisition underpins AuthIntelligence; AI-related capex is expected to be higher in 2027 than 2026, with returns from late 2027.
- Capital expenditure
- $34.1 million of internal-use software and equipment in 2025; capitalized expenditures of $26 million to $28 million guided for 2026.
- New oncology Performance Suite partnership
- An existing advanced imaging client signed an oncology Performance Suite partnership covering about 1.5 million Medicaid and Medicare lives in 11 states, with launch expected by December 2026 and about $300 million of annualized revenue.
Challenges and risks
- Customer concentration
- In Q3 2026 Highmark was 28.1% of revenue, Molina 23.1%, Aetna 12.8% and Cook County Health 11.4%; many specialty contracts are terminable without cause after an initial term on 30 to 180 days' notice.
- Medicaid and exchange membership pressure
- The One Big Beautiful Bill Act's Medicaid and ACA changes are expected to bring higher acuity and lower membership; customers reported Medicaid and Health Exchange membership declines in Q3 2026.
- Rising specialty medical costs under risk contracts
- Medical claims costs grew faster than historical norms in 2024 and 2025, and Evolent anticipates continued growth in the cost of cancer and cardiovascular treatment, exposing its capitated Performance Suite contracts.
- Leverage
- Net debt was $776 million at Q3 2026, with a $117.2 million term loan, $62.5 million revolver, $175.0 million second-lien loan and $569.25 million of convertible note principal outstanding.
- Scrutiny of prior authorization and AI
- Federal and state scrutiny of prior authorization is rising (CMS-4201-F, state gold carding laws, CMS-0057-F timeframes from January 1, 2026), and at least 40 states introduced or enacted AI legislation in 2024.
What leadership says
“I believe our innovative AI platform and our oncology solution will drive growth and margin expansion for Evolent in the quarters to come.”
“In our core offering, we do not feel like we have direct competitors that can do what we do and the way we do it.”
“we are prioritizing margin and cash generation over revenue growth”
“There's 140+ million auths a year that happen in the U.S. We're doing 9 million of them”
Where a supplier can help
- AI and clinical data tooling
- The AuthIntelligence target of more than 80% of manual auths by end 2027, and higher AI capex in 2027, create room for suppliers of AI infrastructure, clinical data extraction and model governance that respects the no-AI-denial policy.
- Cost reduction and operations efficiency
- The enterprise-wide cost review and the priority on margin and cash point to vendors who lower operating cost in review, call center and offshore operations in Pune and Manila.
- EMR integration for oncology pathways
- Embedding clinical pathways into oncology groups' EMRs and expanding Member Navigation calls for interoperability, integration and patient-engagement capabilities.
- Regulatory compliance for prior authorization
- CMS-0057-F decision timeframes and interface requirements, plus state AI legislation, open a need for compliance, interface and audit tooling around utilization management.
- Launch support for new Performance Suite contracts
- The oncology partnership launching by December 2026 and the January 1, 2027 oncology expansion require provider network, implementation and claims analytics capacity.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like Evolent?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- Evolent Health, Inc. Annual Report on Form 10-K for the fiscal year ended December 31, 2025
- Evolent (NYSE: EVH, Arlington, Virginia) manages specialty care for people with complex conditions, chiefly cancer, cardiovascular disease and musculoskeletal diagnoses, on behalf of health plans and other risk-bearing payers; all revenue is recognized in the United States. About 4,200 employees as of February 16, 2026, with offices in the US, Pune (India) and Manila (Philippines).
- FY2025 revenue fell 26.6% to $1,876.2 million (2024: $2,554.7 million), mainly from moving a customer from the Performance Suite to the Specialty Technology and Services Suite ($447.3 million) and narrowing the scope of other Performance Suite contracts ($267.4 million), both offset by much lower claims expense.
- One reportable segment, sold through four product types: Performance Suite (capitated, $1,127.3 million), Specialty Technology and Services Suite ($353.2 million), Administrative Services ($226.7 million) and Cases ($169.0 million).
- Net loss attributable to common shareholders was $579.4 million, driven by a $398.0 million non-cash goodwill impairment after the share price fell from $23.35 (Oct 31, 2024) to $6.67 (Oct 31, 2025); operating loss $410.1 million.
- Customer concentration is high: Molina 25.7% of 2025 revenue, Cook County Health 16.4%, Florida Blue 14.2%, Centene 12.2%.
- Portfolio refocused: Evolent Care Partners (the ACO / total cost of care business) sold for $100.0 million plus up to $13.0 million contingent, closed December 5, 2025 (cash proceeds $91.3 million, gain $14.9 million); proceeds repaid $82.8 million of term loan.
- Balance sheet rebuilt in 2025: $166.8 million of 2031 convertible notes issued, 2025 notes retired, $40.0 million of shares repurchased, Series A Preferred Stock exchanged for a $175.0 million second-lien term loan; year-end cash $151.9 million.
- AI is a stated lever: the Machinify acquisition underpins Auth Intelligence, which helps reviewers with prior-authorization requests and automates approvals only; company policy forbids using AI to deny care.
- Key risks: dependence on a few large partners, risk-sharing exposure under Performance Suite contracts, Medicaid and ACA membership pressure from the One Big Beautiful Bill Act, scrutiny of prior authorization and AI in utilization management, and leverage.
- Evolent Health, Inc. Quarterly Report on Form 10-Q for the quarter ended September 30, 2026
- Q3 2026 revenue rose 51.3% year on year to $725.4 million, mainly from $280.1 million of new Performance Suite contract go-lives and expanded oncology services for an existing customer.
- Nine-month revenue rose 33.2% to $1,874.1 million despite losing $63.5 million from the Evolent Care Partners disposal and $82.5 million from membership reductions and rate adjustments.
- Performance Suite revenue reached $564.3 million in the quarter (Q3 2025: $286.9 million), with average PMPM up to $26.14 from $14.77; Specialty Technology and Services fell to $72.8 million and Administrative Services to $48.3 million.
- Medical Expense Ratio rose to 93.0% (Q3 2025: 85.0%) after the ECP sale; cost of revenue was 87.8% of revenue, reflecting the maturation profile of two Performance Suite contracts launched in H1 2026.
- New customer concentration: Highmark 28.1% of Q3 revenue, Molina 23.1%, Aetna 12.8%, Cook County Health 11.4%.
- SG&A fell 5.8% to $73.1 million (10.1% of revenue); personnel costs down on reduced headcount and benefit/bonus changes. Operating loss $6.2 million; nine-month net loss attributable to common shareholders $78.6 million.
- Cash $148.3 million at September 30, 2026; term loan $117.2 million, revolver $62.5 million, second-lien loan $175.0 million, plus convertible notes; the company may opportunistically refinance or retire debt.
- Customers reported Medicaid and Health Exchange membership declines in the quarter, in line with Evolent's expectations.
- Evolent Announces Third Quarter 2026 Results (press release, Exhibit 99.1 to Form 8-K)
- Q3 2026 revenue $725.4 million (Q3 2025: $479.5 million); net loss attributable to common shareholders $23.6 million (net loss margin -3.2%); Adjusted EBITDA $34.3 million (4.7% margin, down from 8.1%).
- Full-year 2026 guidance: revenue reiterated at $2.6 billion to $2.7 billion; Adjusted EBITDA raised to $130.0 million to $135.0 million; capital expenditure of $26 million to $28 million.
- One renewal and two new revenue agreements in the quarter, seven year to date: the largest Surgical Management (IPG) customer renewed for four more years.
- An existing client expands oncology services to several additional states, about 1 million Commercial lives, going live January 1, 2027, and adds Member Navigation across all lives.
- A national payer expanded its Specialty Technology & Services oncology relationship to 11 additional states.
- MER 93.0%; Performance Suite PMPM $26.14 on 7,195 thousand average lives; adjusted income per share $0.06.
- CEO Seth Blackley: "I believe our innovative AI platform and our oncology solution will drive growth and margin expansion for Evolent in the quarters to come."
- Evolent Health (EVH) Q3 2026 Earnings Call Transcript
- Q3 2026 revenue $725 million, up 11% on Q2; Adjusted EBITDA $34.3 million, up about 22% sequentially; MER 93% vs 95% in Q2 thanks to favorable in-year claims development and contractual adjustments.
- Guidance: 2026 revenue $2.6 billion-$2.7 billion reiterated, Adjusted EBITDA raised to $130 million-$135 million; 2027 Adjusted EBITDA midpoint expected at $150 million or higher, assuming no policy change.
- Oncology is the core: Blackley expects it to be over 70% of Evolent's 2027 revenue; a national payer client now has about 7 million lives managed by Evolent after adding 11 states to 39.
- AuthIntelligence (from the 2024 Machinify acquisition) now evaluates about half of prior-authorization volume that needed manual review, touching about 1 million cases a year; target more than 80% of manual auths (about 2 million cases) by end 2027.
- Auto-approval rates rose by as much as 20 points (60% to 80% in some cases); a 10% improvement removes about 600,000 manual touches a year out of about 9 million reviews.
- Aetna and Highmark Performance Suite launches show favorable claims run-out; Highmark is "ahead of plan".
- Balance sheet: up to $50 million to be deployed to reduce debt by year end; net debt $776 million; evaluating "capital markets and strategic alternatives".
- 2027 headwinds: Medicaid work requirements, some Administrative Services client attrition, scope adjustments on renewals, AI investment; Evolent is "prioritizing margin and cash generation over revenue growth".
- Evolent Health (EVH) Q2 2026 Earnings Call Transcript
- Q2 2026 revenue $653 million, up 31% on Q1; Adjusted EBITDA $28 million, up 27%; MER 95% vs 93% in Q1, reflecting the Highmark launch on May 1, 2026.
- 2026 guidance raised: revenue $2.6 billion-$2.7 billion (from $2.4 billion-$2.6 billion), Adjusted EBITDA narrowed to $120 million-$135 million; full-year MER about 93%.
- New oncology Performance Suite partnership with an existing advanced imaging client: about 1.5 million Medicaid and Medicare lives in 11 states, launch by December 2026, about $300 million annualized revenue.
- Three of the largest customers renewed in 2026; a regional Blue Cross plan (former NIA customer) broadened its Specialty Technology and Services use (under $5 million annualized revenue).
- Early 2027 view: revenue growth of more than 25% from contracted business and renewals; Adjusted EBITDA midpoint at or above $150 million despite Medicaid and exchange headwinds.
- AI: more than a third of manually reviewed authorization volume now runs through Auth Intelligence; auto-approval up to 20 points higher (e.g. 55% to 75%); long-term goal to auto-approve 80% of authorization volume.
- Capital structure: CFO Mario Ramos is "personally most focused" on it; aims to improve leverage and 2029 maturities within 12-24 months via EBITDA growth, cash conversion, capital markets and "strategic options".
- Blackley: Evolent has 6.7 million Performance Suite lives, "less than 2% of the country"; drugs are about 75% of oncology cost.
Questions about Evolent
What does Evolent do?
Evolent manages specialty care for people with complex conditions, chiefly cancer, cardiovascular disease and musculoskeletal diagnoses, on behalf of US health plans and other risk-bearing payers. It combines specialist networks, clinical pathways and proprietary technology, and takes on claims risk in its capitated Performance Suite.
What is Evolent's revenue?
FY2025 revenue was $1,876.2 million, down 26.6%. Q3 2026 revenue was $725.4 million, and 2026 revenue guidance is $2.6 billion to $2.7 billion.
How many employees does Evolent have?
About 4,200 employees as of February 16, 2026, with offices in the US, Pune (India) and Manila (Philippines).
Who leads Evolent?
Seth Blackley, co-founder, has been CEO since October 2020; Dan McCarthy is President and Mario Ramos has been CFO since January 2026.
What is Evolent's strategy?
Evolent is centering on oncology, expected to be over 70% of 2027 revenue, and on AI for prior-authorization review through AuthIntelligence, while prioritizing margin and cash generation and reducing debt.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)